secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-269514
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Impel Pharmaceuticals CEO Adrian Adams resigns; CCO Len Paolillo named interim CEO
--------------------------------------------------------------------------------

- Adrian Adams resigned as Chairman, President and CEO effective Nov. 4, 2023; no disagreement cited.
- Leonard S. Paolillo, current Chief Commercial Officer, appointed Interim President and CEO.
- Paolillo joined Impel in March 2021; previously EVP & CCO at Kyowa Kirin North America.
- Board to formally appoint Paolillo upon Adams's departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/0001193125-23-269514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000119312523269514/d397416d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-269514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer